HDAC3 Polyclonal Antibody

Histone deacetylase 3 (HDAC3) is a zinc-dependent metalloenzyme and class I HDAC.^1,2 It is ubiquitously expressed and localizes primarily to the nucleus but also to the cytoplasm and plasma membrane. HDAC3 forms a complex with nuclear receptor co-repressor (NCOR) and silencing mediator of retinoic thyroid receptors (SMRT) to deacetylate histones and induce transcriptional repression and can be recruited to sites bound by activating transcription factor 2 (ATF2) without NCOR to induce inflammatory gene expression, indicating a role in transcriptional activation.^2,3 HDAC3 activity is correlated with various diseases, including cancer, metabolic disorders, autoimmune disorders, neurodegenerative and CNS disorders, and cardiovascular disease.⁴ Cayman’s HDAC3 Polyclonal Antibody can be used for chromatin immunoprecipitation (CHiP), immunoprecipitation (IP), and Western blot (WB) applications.

WARNING This product is not for human or veterinary use.

1. Huang, L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J. Cell. Physiol. 209(3), 611-616 (2006).

2. Sarkar, R., Banerjee, S., Amin, S.A., et al. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review. Eur. J. Med. Chem. 192, 112171 (2020).

3. Nguyen, H.C.B., Adlanmerini, M., Hauck, A.K., et al. Dichotomous engagement of HDAC3 activity governs inflammatory responses. Nature 584(7820), 286-290 (2020).

4. Adhikari, N., Jha, T., and Ghosh, B. Dissecting histone deacetylase 3 in multiple disease conditions: Selective inhibition as a promising therapeutic strategy. J. Med. Chem. 64(13), 8827-8869 (2021).